Our (e)Books and (e)Journals
IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.
Browse by Subject
- Administrative Sciences
- Biochemistry, Medicine & Health
- Computer & Communication Sciences
- Environmental Sciences
- Food & Nutrition
- Geographic Information Science
IOS Press publishes books and journals (online and in print) in a broad range of scientific, technical and medical (STM) subject areas. Click on a subject above to see our titles.
NewsKeep me informed
August 2, 2021 - Amsterdam, NL – Every year there are nearly ten million new cases of dementia globally, of which Alzheimer’s disease (AD) is the most common form, accounting for around 60–70% of cases. This special supplement, published in the Journal of Alzheimer’s Disease, focuses on the challenges posed by brain disease and presents significant research contributions from Latin America and the Caribbean that address these challenges to help improve the lives of individuals with AD.August 2, 2021
July 29, 2021 - Prague, Czechia – According to a study published in Journal of Alzheimer's Disease, people born in winter seem to carry a life-long disadvantage in cognitive ageing. Specifically, their cognitive skills are lower when compared to people born in other seasons, even when taking into account other influencing characteristics, such as their education, depression or cardiovascular diseases.July 29, 2021
July 28, 2021 - Amsterdam, NL – IOS Press, an independent international publisher of scientific, technical, and medical (STM) journals and books, is pleased to announce significant increases in the Journal Impact Factors (JIFs) of two of its flagship journals in neurogenerative diseases. The Journal of Parkinson’s Disease JIF has increased by 7.5% to 5.568, positioning it in the first quartile of Neuroscience journals with a ranking of 62 among 270 journals in that category. The Journal of Alzheimer’s Disease, the most highly cited journal devoted exclusively to this disease, rose by an impressive 14.4% to 4.472.July 28, 2021
Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors
July 27, 2021 - St. Louis, MO, USA – Keystone Bio, a biotechnology company, is a frontrunner in developing precision biologics to eliminate Porphyromonas gingivalis (Pg) and is releasing groundbreaking data that shows bacterial toxic proteins from Pg in the mouth are released into the blood and cross the blood-brain barrier (BBB) as the major driver of sporadic Alzheimer’s disease (AD) and chronic inflammation.July 27, 2021